It has also been observed in clinical trials of anti-VEGF monotherapy that when treatment leads to CNV regression in nAMD, patients may be left with macular atrophy and fibrosis at the site of regression; however, if type 1 MNV is appropriately treated, there may be protection from macular atrophy and fibrosis [73, 74]. This evidence concerns the gene VEGFA and fibrosis.